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A lupine (Lupinus angustifolious L.) peptide
prevents non-alcoholic fatty liver disease in
high-fat-diet-induced obese mice†
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Lourdes M. Varela, c Carmen Claro,d Justo Pedroche,a Francisco Millan,a
Maria C. Millan-Linares *a,e and Sergio Montserrat-de la Paz b
Bioactive peptides are related to the prevention and treatment of many diseases. GPETAFLR is an octa-
peptide that has been isolated from lupine (Lupinus angustifolius L.) and shows anti-inflammatory pro-
perties. The aim of this study was to evaluate the potential activity of GPETAFLR to prevent non-alcoholic
fatty liver disease (NAFLD) in high-fat-diet (HFD)-induced obese mice. C57BL/6J mice were fed a stan-
dard diet or HFD. Two of the groups fed the HFD diet were treated with GPETAFLR in drinking water at
0.5 mg kg−1 day−1 or 1 mg kg−1 day−1. To determine the ability of GPETAFLR to improve the onset and
progression of non-alcoholic fatty liver disease, histological studies, hepatic enzyme profiles, inflamma-
tory cytokine and lipid metabolism-related genes and proteins were analysed. Our results suggested that
HFD-induced inflammatory metabolic disorders were alleviated by treatment with GPETAFLR. In con-
clusion, dietary lupine consumption can repair HFD-induced hepatic damage possibly via modifications
of liver’s lipid signalling pathways.
Introduction
Nowadays, the population is growing exponentially and mean-
while, natural sources are decreasing due to their overexploita-
tion and climate change. For these reasons, it is necessary to
discover new sources of nutritional compounds that have
nutritional value and can be easy to obtain and process. This
research opens a novel area that takes advantage of agroindus-
try by-products to further propose adaptive supply regarding
the specific demand of nutrients and bioactive compounds.1,2
Vegetables are an important source of nutrients. The iso-
lation and purification of peptides are relatively easy; more-
over, their growth procedure is cheap and simple. Therefore,
peptides are an ideal target for obtaining bioactive com-
pounds. The main sources of peptides are soy, eggs, milk, and
fish.3 The main ways by which the bioactive peptides act on
human health are as follows: decreased inflammation, lower
blood pressure, anti-obesity, and prevention and improvement
in the symptoms related to diabetes.4 In addition, the diseases
that are on the rise in developed countries such as obesity, dys-
lipidemias, type II diabetes, metabolic syndrome, and non-
alcoholic fatty liver disease (NAFLD) have pharmacological
treatment that is not fully effective and also has adverse side
effects.5 This is why many scientists are looking for substances
of plant origin that can alleviate or prevent these diseases.6
Bioactive peptides contain a short sequence of amino acids
with different biological activities. Initially, they are found in
protein precursors in the organism of origin and they are gen-
erally not active.7,8 Peptides are obtained from plant proteins
as a result of enzymatic hydrolysis during digestion via fermen-
tation by micro-organisms or by in vitro chemicals or enzy-
matic hydrolysis processes.7
Lupinus angustifolius L. is one of the targets for the research
of such peptides because it has a high amount of proteins and
low fat content.9,10 GPETAFLR is an octapeptide isolated from
Lupinus angustifolius L. with the sequence glycine-proline-
glutamic acid-threonine-phenylalanine-leucine-arginine. This
peptide features a three-dimensional secondary structure of
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α-helix (Fig. 1). Its immunomodulatory and anti-inflammatory
capacities have been demonstrated.11 Its effects have been pre-
viously investigated in macrophage THP-1-line derivatives,11
osteoclasts derived from human primary monocytes,12 and
primary human monocytes.13 Hence, it is an interesting
compound to treat or prevent diseases characterized by
inflammation.
Non-alcoholic fatty liver disease (NAFLD) is a health
problem that affects a large percentage of the world’s popu-
lation with a global prevalence of 25%.14 The prevalence of
this disease is very common in developed countries due to the
fact that it typically occurs in people with obesity, type 2 dia-
betes, and metabolic syndrome among other pathologies
related to lifestyle.15–18 NAFLD consists of the accumulation of
fat in the liver tissue, which is derived from a high amount of
free fatty acids (FFAs) and triglycerides (TGs) in the circulating
blood. These levels may increase after higher caloric and fat
intakes. For this reason, fatty liver disease is often associated
with obesity and dyslipemias.15–18 The best models for the
study of this disease are animal models of induced obesity;
specifically, mice and rat models present pathogenesis more
similar to humans.19 NAFLD has 4 phases: non-alcoholic fatty
liver (NAFL), accumulation of fat in the liver; non-alcoholic
steatohepatitis (NASH), liver fat accumulation with inflam-
mation; fibrosis, accumulation of fat and inflammation result-
ing in tissue damage that drifts into fibrosis; and cirrhosis,
most of the cells are replaced by fibrosis, thus considerably
damaging the cellular hepatic function. This state leads to
hepatic dysfunctionality, and the development of NAFLD may
culminate in the development of liver cancer.18 Specifically,
cirrhosis (last stage of NAFLD) is the major risk factor for
developing hepatocellular carcinoma, the most common liver
cancer. Hepatic steatosis is also related to the occurrence of
hepatocellular carcinoma.20 Thus, NAFLD, even in its early
stages, promotes the development of the most common type
of liver cancer. Herein, the peptide GPETAFLR was used to
investigate its role in the development of NAFLD in the hepatic
tissues of mice with HFD-induced obesity.
Materials and methods
All animal protocols received appropriate institutional
approval (Animal Care and Use Committee of the University of
Seville) and were performed according to the official rules for-
mulated in the Spanish law on the care and use of experi-
mental animals (UE Directive of 2010: 2010/63/UE; RD 53/
2013).
Isolation, purification, and synthesis of GPETAFLR
Seeds of sweet lupine (Lupinus angustifolius L.) were a gift from
Koipesol Semillas, S.A. (Seville, Spain). Alcalase 2.4 L was pro-
vided by Novozymes (Bagsvaerd, Denmark). Lupine protein
isolate was obtained using a previously described method at
the pilot plant scale (Plant Protein Unit, Instituto de la Grasa,
Seville, Spain).21 The chemical composition of lupine protein
isolate in dry matter was as follows: protein 86.83%, dietary
fiber 5.97%, fat 5.08%, ash 0.78%, and carbohydrate 1.34%.
Lupine protein isolate was suspended in distilled water (10%
w/v), and hydrolysis with Alcalase was performed under the fol-
lowing conditions: pH 8, 50 °C, E/S = 0.3 AU g−1 protein, and a
hydrolysis time of 15 min. The mixture was then heated at
85 °C for 15 min to inactivate the enzyme and centrifuged at
6500g for 15 min, and the supernatant constituted LPH.11 This
fraction was purified by ultrafiltration and chromatographic
techniques.22 The sequence of the purified peptide was identi-
fied through sequence analysis using nano-HPLC coupled with
a Polaris Q ion-trap mass spectrometer (Mass Spectrometry
Unit, Instituto de la Grasa, Seville, Spain). Finally, the peptide
was synthesized by an Fmoc solid-phase method (Barcelona
Scientific Park Foundation, Barcelona, Spain) at 95% purity
measured using HPLC-UV at 220 nm.
Animal diets and experimental design
In order to keep the experimental number of mice as low as
possible, forty male mice C57BL/6J were used in the study.
They were obtained from the Animal Production and
Experimentation Centre at the University of Seville. The mice
Fig. 1 Chemical (a) and secondary three-dimensional (b) structures of GPETAFLR peptide, an octapeptide isolated from Lupinus angustifolius L., for
which the amino acid sequence is identified as Glycine (G), Proline (P), Glutamate (E), Threonine (T), Alanine (A), Phenylalanine (F), Leucine (L), and
Arginine (R). Yellow color was used for the side chain, green color was used for the amino group, and blue color was used for the carboxyl group.
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were divided into four groups (n = 10 per group), in which 3 of
them were fed HFD and the last group was fed a standard
chow diet (CD) and was used as a control group (210 SAFE,
Augy, France). Mice were fed for 8 weeks. The HFD, which con-
tained 60% energy as fat, was prepared by Panlab Laboratories
(HF 260 SAFE) and presented as pellets to the animals
(Table 1). Two of the experimental animal groups fed HFD
were also treated with the synthesized GPETAFLR peptide,
which was added into drinking water and administered at a
dose of 0.5 or 1 mg kg−1 day−1. Mice were anesthetized by an
intraperitoneal injection of ketamine (100 mg kg−1) and diaze-
pam (5 mg kg−1) and then euthanized by cervical dislocation.
Hepatic tissues were immediately removed and then frozen at
−80 °C until processing. Homogenization was done with
TRIsure (Bioline, Memphis, TN, USA).
Dosage information
Doses of 0.5 and 1 mg kg−1 day−1 of the synthesized GPETAFLR
peptide were established according to previous studies23–28 and
the expected water consumption of the C57BL/6J strain.29 These
selected doses for animals were comparable to human equi-
valent doses (HED) of 40 and 80 µg kg−1.30
RNA isolation and real-time quantitative PCR analysis
RNA from hepatic tissues was isolated to quantify gene
expression by RT-qPCR. Total RNA was extracted by using
TRIsure Reagent (Bioline). RNA quality was assessed by the
A260/A280 ratio using a NanoDrop ND-1000 Spectrophotometer
(Thermo Fisher Scientific, Madrid, Spain). Briefly, RNA (250
ng) was subjected to reverse transcription (iScript, Bio-Rad).
An amount of 40 ng of the resulting cDNA was used as a tem-
plate for RT-qPCR amplifications. The mRNA levels for specific
genes were determined in a CFX96 system (Bio-Rad). For each
PCR reaction, a cDNA template was added to Brilliant SYBR
green QPCR Supermix (Bio-Rad) containing the primer pairs
for either gene or hypoxanthine phosphoribosyltransferase
(HPRT) as a housekeeping gene. All amplification reactions
were performed in triplicate and the average threshold cycle
(Ct) numbers of the triplicates were used to calculate the rela-
tive mRNA expression of the candidate genes. The magnitude
of the change in the mRNA expression for candidate genes was
calculated by using the standard 2−(ΔΔCt) method. All data
were normalized to endogenous reference (HPRT) gene
content and expressed as relative fold-change of control. The
sequences of the designed oligonucleotides are shown in
Table S1.†
Histological analysis
Dissected liver sections were fixed overnight with 4% parafor-
maldehyde, cryoprotected with 15%–30% sucrose and
embedded in Tissue-Tek OCT embedding medium (Sakura
Finetek Europe, The Netherlands). Cryostat sections
(8–10 microns) were rinsed with PBS and stained with a 0.3%
solution of Oil Red O for 10 minutes at room temperature.
After washing in PBS, the sections were counterstained with
hematoxylin and eosin for 1 minute and washed with water.31
The percentage of the stained area was determined using
Image J software.
Biochemical analysis
The levels of leptin in supernatants were measured by ELISA
following the indications of the manufacturer (ThermoFisher).
The adipokine concentrations were expressed in ng per mL, as
calculated from the calibration curves from a serial dilution of
mice recombinant standards. In addition, the TG content in
serum and liver tissues was determined by colorimetric
enzyme assays (Bio-Science-Medical). The enzyme activities of
liver enzymes, alkaline phosphatase (ALP), aspartate amino-
transferase (AST), alanine aminotransferase (ALT) and lactate
dehydrogenase (LDH) were measured using a commercial kit
(Bio-Science-Medical) following the instructions. Absorbance
was read using a microplate reader.
Statistical analysis
All values in the figures and text are expressed as the arith-
metic mean ± SD. Experiments were carried out in triplicate.
Data were evaluated with GraphPad Prism Version 7.0 software
(San Diego, CA, USA). The statistical significance of any differ-
ence in each parameter among the groups was evaluated by
one-way analysis of variance (ANOVA) using Tukey’s test for
multiple comparison analyses. P values < 0.05 were considered
statistically significant.
Results
GPETAFLR decreases body and liver weight gain in HFD-
induced obese mice
After 8 weeks of diet, the animals showed body weight gain
(Fig. 2(a)), and the increase in the body weight of the groups
fed HFD was higher than that for the control group (Fig. 2(b)).
Weight gain during the 8 weeks with HFD and GPETAFLR
treatment at 1 mg kg−1 day−1 was significantly lower (1.3-fold
lower for HFD-GPETAFLR (1 mg kg−1 day−1) than HFD) than
that for animals fed HFD not containing the peptide. Liver
weight was also significantly higher in the obese control
(animals fed only HFD) (1.3-fold lower for HFD-GPETAFLR
(1 mg kg−1 day−1) than HFD) with respect to that for the
animals treated with GPETAFLR in drinking water (Fig. 2(c)).
Table 1 Composition of standard chow and high-fat diets
Macronutrients kcal kg−1 %kcal
Standard chow diet (amount per kg)
Protein 205.9 g 823.8 23.3
Fat 55.1 g 496.4 14
Carbohydrates 554.2 g 2216.8 62.7
Total 815.2 g 3537 100
High-fat diet (amount per kg)
Protein 200.2 g 800.9 1.6
Fat 359.4 g 3235.2 58.8
Carbohydrates 374.1 g 1496.3 26.7
Total 933.7 g 5505.4 100
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In line with the results described above, the level of TGs in the
blood was significantly higher in the obese control group (2.1-
fold higher for HFD than HFD-GPETAFLR (1 mg kg−1 day−1))
with respect to that in the animals that, in addition to HFD,
were treated with GPETAFLR in their drinking water (Fig. 2(d)).
In this case, similar to that observed for liver weight, the effect
of GPETAFLR was dose-dependent.
GPETAFLR decreases hepatic leptin resistance in HFD-induced
obese mice
In obesity, the blood levels of leptin increase due to the lack of
sensitivity between leptin and its receptor (OB-R), which is
similar to that observed in insulin resistance. After 8 weeks of
HFD, mice presented higher serum levels of leptin than the
animals fed the standard diet (4.2-fold higher for HFD than
CD) (Fig. 3(a)). The treatment with GPETAFLR significantly
decreased these levels (2.7-fold lower for HFD-GPETAFLR
(1 mg kg−1 day−1) than HFD). Similarly, the OB-R mRNA levels
were significantly higher in the animals fed HFD in contrast to
that in the animals that did not receive GPETAFLR through
drinking water (3.9-fold lower for HFD-GPETAFLR (1 mg kg−1
day−1) than HFD, Fig. 3(b)).
GPETAFLR decreases hepatic steatosis in HFD-induced obese mice
Fig. 4 shows the results of the histological study carried out
with ORO and H&E staining for the determination of the lipid
content in hepatocytes. Fig. 4(a) shows the representative stain-
ing images of the histological slices of livers obtained from
each experimental group. After 8 weeks of HFD, mice pre-
sented higher levels (3.2-fold higher for HFD than CD) of
hepatic lipids than the animals fed a standard diet (Fig. 4(b)).
The mice treated with GPETAFLR exhibited significant
decrease in the hepatic steatosis induced by HFD (1.9-fold
lower for HFD-GPETAFLR (1 mg kg−1 day−1) than HFD).
GPETAFLR modulates hepatic lipid metabolism-related genes
in HFD-induced obese mice
After 8 weeks of HFD, the levels of TGs in liver tissues were
higher compared to that for CD (5.2-fold higher for HFD than
CD, Fig. 5(a)). However, the TG levels were lower in the
animals that were fed HFD and received GPETAFLR treatment
(2.7-fold lower for HFD-GPETAFLR (1 mg kg−1 day−1) than
HFD). Significantly, GPETAFLR at 1 mg kg−1 day−1 restored the
values of CD. In line with these results, the expression of the
fatty acid synthase (FAS) enzyme (Fig. 5(b)) and peroxisome
proliferator-activated receptor α (PPARα) were determined
(Fig. 5(c)). The FAS mRNA levels in the animals fed HFD were
significantly higher than those in the animals fed CD
(33.6-fold higher for HFD than CD) or treated with GPETAFLR
(18.6-fold higher for HFD than CD). In addition, the trans-
criptional activity of PPARα increased in the groups that
received the octapeptide (6.6-fold higher for HFD-GPETAFLR
Fig. 2 Effect of GPETAFLR on the evolution of body weight (a), percentage of body weight gain (b), liver weight (c) and blood triglyceride levels (d)
in mice fed a standard chow diet (CD), an HFD or an HFD + GPETAFLR at a dose of 0.5 mg kg−1 day−1 and 1 mg kg−1 day−1 in drinking water. Values
are presented as means ± SD (n = 10) and those marked with different letters are significantly different (P < 0.05).
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(1 mg kg−1 day−1) than HFD). Finally, the mRNA levels of mito-
chondrial decoupling protein 1 (UCP1) were determined
(Fig. 5(d)). The treatment with GPETAFLR in drinking water
significantly increased the hepatic transcriptional activity of
UCP1 in comparison to those groups that did not receive the
peptide (4.9-fold higher for HFD-GPETAFLR (1 mg kg−1 day−1)
than HFD).
GPETAFLR decreases hepatic inflammation in HFD-induced
obese mice
After 8 weeks of HFD, the gene expressions of proinflammatory
cytokines on hepatic tissues such as tumor necrosis factor α
(TNF-α) (Fig. 6(a)), interleukin 1β (IL-1β) (Fig. 6(b)), and inter-
leukin 6 (IL-6) (Fig. 6(c)) were significantly higher in the
animals fed exclusively with HFD. In both doses, GPETAFLR
significantly decreased the mRNA levels of the pro-inflamma-
tory cytokines. The gene expression of the anti-inflammatory
cytokine interleukin 10 (IL-10) significantly increased in the
mice that received GPETAFLR in drinking water compared to
that in the groups that did not receive the peptide (5.1-fold
higher for HFD-GPETAFLR (1 mg kg−1 day−1) than HFD,
Fig. 6(d)).
GPETAFLR decreases blood markers of liver damage in HFD-
induced obese mice
After 8 weeks of HFD, mice showed higher serum activity for
AST (5.1-fold higher for HFD than HFD-GPETAFLR (1 mg kg−1
day−1), Fig. 7(a)) and ALT (8.2-fold higher for HFD than
HFD-GPETAFLR (1 mg kg−1 day−1), Fig. 7(b)) than those
animals that received the GPETAFLR peptide in drinking
water. GPETAFLR restored the values of transaminases to the
levels in the animals fed CD. The activity of serum ALP was sig-
nificantly higher in the obese control (1.4-fold higher for HFD
than HFD-GPETAFLR (1 mg kg−1 day−1), Fig. 7(c)). GPETAFLR
at 1 mg kg−1 day−1 restored the values of this marker to
similar levels to the animals fed CD. On the other hand, the
values for the serum activity of the enzyme LDH were higher in
the obese control (2.8-fold higher for HFD than
Fig. 3 Effect of GPETAFLR on leptin resistance. Serum leptin levels (a) and gene expression in leptin receptor hepatic tissue (OB-R) (b) in mice fed a
standard chow diet (CD), an HFD or an HFD + GPETAFLR at a dose of 0.5 mg kg−1 day−1 and 1 mg kg−1 day−1 in drinking water. Values are presented
as means ± SD (n = 10) and those marked with different letters are significantly different (P < 0.05).
Fig. 4 Effect of GPETAFLR on hepatic steatosis. Representative images
(10×) of stained histological slices with Oil Red O (ORO) and hematoxy-
lin–eosin (H&E) (a) and quantification of the stained area with ORO from
each experimental group (b) in mice fed a standard chow diet (CD),
an HFD or an HFD + GPETAFLR at a dose of 0.5 mg kg−1 day−1 and
1 mg kg−1 day−1 in drinking water. Values are presented as means ± SD
(n = 10) and those marked with different letters are significantly different
(P < 0.05).
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Fig. 5 Effect of GPETAFLR on the TG levels in the liver tissue (a) and the expression of genes related to lipid and energy metabolism, such as the
fatty acid synthase (FAS) (b), peroxisome proliferator-activated receptor α (PPARα) (c) and uncoupling protein 1 (UCP1) (d) in mice fed a standard
chow diet (CD), an HFD or an HFD + GPETAFLR at a dose of 0.5 mg kg−1 day−1 and 1 mg kg−1 day−1 in drinking water. Values are presented as means
± SD (n = 10) and those marked with different letters are significantly different (P < 0.05).
Fig. 6 Effect of GPETAFLR on the expression of pro-inflammatory and anti-inflammatory cytokine genes in mice fed a standard chow diet (CD), an
HFD or an HFD + GPETAFLR at a dose of 0.5 mg kg−1 day−1 and 1 mg kg−1 day−1 in drinking water. The mRNA levels of TNF-α (a), IL-1β (b), IL-6 (c)
and IL-10 (d) were measured in the liver tissue. Values are presented as means ± SD (n = 10) and those marked with different letters are significantly
different (P < 0.05).
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HFD-GPETAFLR (1 mg kg−1 day−1), Fig. 7(d)). GPETAFLR at
1 mg kg−1 day−1 significantly decreased the values of this
enzyme compared to that for the mice fed HFD without the
GPETAFLR treatment.
Discussion
The use of bioactive peptides obtained from food is increas-
ingly gaining importance because of their health benefits and
use in preventing chronic diseases, whose incidences are
increasing worldwide.4 Many chronic diseases are character-
ized by a marked inflammatory process. Therefore, GPETAFLR,
a novel anti-inflammatory biopeptide obtained from Lupinus
angustifolius L., can be a potent molecule for the prevention of
these types of diseases. Its anti-inflammatory activity has been
demonstrated. Specifically, both the peptide and the extracts
of hydrolyzed lupin proteins have shown the ability to decrease
the expression of pro-inflammatory cytokines and increase the
expression of anti-inflammatory cytokines.11–13
The liver is the main metabolic organ of the body. NAFLD
affects its functionality, endangering the homeostasis meta-
bolic system. This disease is typically associated with
obesity,15–18 where a substance that has the effect of reducing
body weight and obesity rates will greatly alleviate the symp-
toms and development of NAFLD. The octapeptide GPETAFLR
prevents the weight gain resulting from a diet rich in fat in
contrast to other substances such as isoliquiritigenin with
hepatoprotective properties that do not have the capacity to
prevent weight gain.32 It can be said that GPETAFLR interferes
by preventing the progression of the main cause of NAFLD:
obesity.
On the other hand, the obtained data corroborated that the
HFD-induced obese mice presented NAFLD pathophysiology
similar to humans. The pathophysiology of this disease is
characterized by increased body weight and liver weight, high
levels of TGs in the blood, fat accumulation in adipose tissues,
hepatic inflammation and elevated markers of liver damage.33
In our study, the obese control group showed a greater liver
weight derived from a greater accumulation of fat in the liver.
The accumulation may be due to high levels of TGs in the
blood and the increase in the FAS gene expression. In
addition, this group presented a pro-inflammatory state pro-
voked by high levels of the expressions of pro-inflammatory
cytokines IL-6, IL-1β, and TNF-α since the Kupffer cells
increase their expression in response to hepatic fat accumu-
lation.34 Finally, it presented elevated markers of liver damage
since the activities of transaminases, LDH, and ALP in serum
were significantly higher. These values were also obtained in
other similar studies on HFD-induced obese animals.19,32,35–37
All these parameters of the pathology were palliated with the
treatment with GPETAFLR owing to the fact that liver weight
Fig. 7 Effect of GPETAFLR on serum liver damage markers such as aspartate aminotransferase (AST) (a), alanine aminotransferase (ALT) (b), alkaline
phosphatase (ALP) (c) and lactate dehydrogenase (LDH) (d) in mice fed a standard chow diet (CD), an HFD or an HFD + GPETAFLR at a dose of
0.5 mg kg−1 day−1 and 1 mg kg−1 day−1 in drinking water. CD, chow diet, was used as a control group. Values are presented as means ± SD (n = 10)
and those marked with different letters are significantly different (P < 0.05).
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and liver fat accumulation were lower in the animals treated
with the octapeptide. The factors that can influence the minor
accumulation of hepatic fat in these individuals are a decreased
gene expression of FAS and an increased expression of the
enzymes that increase energy metabolism, such as UCP1 and
PPARα. In addition, there is less circulation of TGs in the blood
and the availability for its accumulation in different tissues
including the liver. GPETAFLR could mediate the accumulation
of hepatic fat by influencing the signaling pathways involved in
the regulation of the gene expression or the activity of lipid
metabolism proteins, such as the kinase pathway activated by
AMP (AMPK). AMPK regulates the activity and expression of
many important proteins related to metabolism; one of them is
mTOR, another metabolic regulator. AMPK decreases the
accumulation of fat (down-regulating FAS, between other pro-
teins) and other metabolites and also down-regulates mTOR,
the protein that increases the accumulation of fat and also has
effects on the gene and protein expressions.38 In previous
studies, GPETAFLR has been demonstrated to present anti-
inflammatory activity that is also exhibited by hepatocytes. The
octapeptide decreased pro-inflammatory cytokine levels and
increased the levels of the anti-inflammatory cytokine IL-10.
IL-10 did not show a decrease in expression in the obese control
compared to that in the standard control, but its expression
greatly increased in the groups treated with GPETAFLR. These
data are related to previous studies on other cell lines and
primary cultures.11–13 Pro-inflammatory cytokines present
several actions related to metabolism; for example, TNF-α
decreases the degradation of fats and increases their accumu-
lation, and IL-6 inhibits lipolysis and increases fat
deposition.35,39 For this reason, in addition to contributing to
tissue damage from chronic inflammation, they contribute to
the development of NAFLD by boosting fat accumulation in the
liver. Chronic inflammation is primarily mediated by the
nuclear factor κB (NF-κB) pathway, which stimulates the pro-
duction of cytokines such as TNF-α.40 For this reason,
GPETAFLR may decrease inflammation by influencing the NF-
κB pathway. The NF-κB pathway increases the expression of pro-
inflammatory cytokines; this pathway can be activated by the
interaction of free fatty acids with TLR4, a membrane receptor
expressed by Kupffer cells, which produces a pro-inflammatory
state.34 The down-regulation of this pathway can be determined
by the reduction in fat accumulation in the liver associated with
the treatment with GPETAFLR.
Another parameter used as a marker of NAFLD pathogen-
esis in this study was the measurement of blood markers for
liver damage, specifically transaminases, ALP, and LDH. The
activity of these enzymes in serum was lower in both
GPETAFLR treatments compared to that in the obese control
group. This effect is probably due to the fact that the peptide
decreases liver damage by reducing the accumulation of fat
and inflammation (influenced by the lower accumulation of
fat) and thus all the tissue damage associated with a chronic
inflammatory process.
On the other hand, leptin is an adipokine produced by
adipose tissues, and the levels of this hormone in the blood
are indicative of the body’s fat reserves because it is produced
proportionally to the amount of adipose tissues. Therefore, a
higher amount of leptin results in a higher amount of fat
reserve.41 Leptin resistance is a characteristic of most obesity-
associated diseases. This syndrome is characterized by a rise
in serum leptin due to the increase in adipose tissues, but
there is a lack of its signaling because the tissues with recep-
tors show resistance. A proof that leptin resistance is occurring
is a high value of leptin in serum and the gene expression of
its receptor in the tissues that express it, such as that observed
in the animals of the obese control group. The liver is one of
the organs that can present receptors for leptin and signaling
by this molecule increases the catabolic metabolism, increases
the degradation of fatty acids, decreases the synthesis of
fatty acids and affects glucose metabolism, specifically
hypoglycemia.41,42 Leptin resistance in NAFLD can mediate an
increase in the accumulation of hepatic fat in its direct form
by a lack of signaling in the liver. In addition, leptin resistance
may enhance the progression of NAFLD due to its role in
intake and satiety. Leptin can cross the blood–brain barrier
once inside the central nervous system (CNS), activate the pro-
duction of anorexigenic peptides and inhibit the production of
orexigenic peptides. This role translates into the inhibition of
appetite and therefore into a decrease in caloric intake.41
Supplementation with GPETAFLR produced a decrease in
obesity-associated leptin resistance. These effects may be due
to the fact that GPETAFLR decreases body weight or
GPETAFLR decreases resistance to the leptin and therefore,
there is a decrease in body weight. It may also be considered
that both effects are produced. Other plant bioactive sub-
stances have been shown to have effects by decreasing the re-
sistance to leptin without significantly affecting the body
weight.32
Conclusions
To conclude, GPETAFLR decreased body weight gain, liver
weight and fat accumulation in the liver as well as TG levels in
the blood and leptin resistance associated with obesity.
GPETAFLR showed anti-inflammatory properties at the hepatic
level, decreasing the mRNA levels of pro-inflammatory cyto-
kines such as TNF-α, IL-6 and IL-10 and increasing the
expression of the anti-inflammatory cytokine IL-10 in liver
tissues. The octapeptide also reduced blood markers related to
liver damage such as AST, ALT, ALP, and LDH. Taken together,
our findings suggest that the use of GPETAFLR is a potential
treatment as well as an important preventive therapy for
NAFLD. Thus, the dietary supplementation with Lupinus angu-
stifolius L. would also contribute to a reduction in this
pathology.
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